Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Dalzanemdor

From Wikipedia, the free encyclopedia
(Redirected fromSAGE-718)
Chemical compound
Pharmaceutical compound
Dalzanemdor
Clinical data
Other namesSAGE-718
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChemCID
ChemSpider
KEGG
ChEMBL
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1
3D model (JSmol)
  • C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CC[C@](C4)(C)O)C
  • InChI=InChI=1S/C26H41F3O2/c1-16(9-14-25(4,31)26(27,28)29)21-7-8-22-20-6-5-17-15-23(2,30)12-10-18(17)19(20)11-13-24(21,22)3/h5,16,18-22,30-31H,6-15H2,1-4H3/t16-,18+,19-,20-,21-,22+,23+,24-,25+/m1/s1
  • Key:RTBRKGVJBGKMFF-YMEFNWBESA-N

Dalzanemdor (INNTooltip International Nonproprietary Name;[1] development codeSAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[2] It acts as a positiveallosteric modulator of theNMDA receptor, whose activity is essential for learning, memory, and cognition.[3] Dalzanemdor is ananalogue of theneurosteroid24S-hydroxycholesterol.[3]

As of 2022, dalzanemdor is inPhase II clinical trials[3] forAlzheimer's disease,[4][5][6]Parkinson's disease, andHuntington's disease.[7][8]

References

[edit]
  1. ^"Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor".Sage Therapeutics. December 5, 2023.
  2. ^Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-ClassN-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment".Journal of Medicinal Chemistry.65 (13):9063–9075.doi:10.1021/acs.jmedchem.2c00313.PMID 35785990.S2CID 250250073.
  3. ^abc"SAGE-718".ALZFORUM.
  4. ^Shapiro L (5 April 2022)."#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's".BioNews, Inc.
  5. ^"SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study"(PDF).American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  6. ^Castañeda R (16 November 2021)."Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion".Clinical Trials Arena. Archived fromthe original on 28 May 2022. Retrieved13 July 2022.
  7. ^"Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718".Huntington's Disease Society of America. 22 February 2022.
  8. ^Wexler M (21 September 2021)."SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy".BioNews, Inc.

External links

[edit]
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
KARTooltip Kainate receptor
NMDARTooltip N-Methyl-D-aspartate receptor


Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dalzanemdor&oldid=1329036504"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp